Literature DB >> 11299728

Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound.

D Gingras1, A Renaud, N Mousseau, E Beaulieu, Z Kachra, R Béliveau.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) play an important role in tissue remodeling under normal physiological and pathological conditions and are thus attractive targets for both diagnostic and therapeutic purposes. Here, we examined the effect of AE-941, an orally bioavailable standardized extract made of cartilage that shows significant antiangiogenic and antimetastatic properties in vivo, on the activity of various members of the MMP family.
MATERIALS AND METHODS: The effect of AE-941 on the activity of MMPs was assessed by fluorimetric assays and by substrate gel zymography.
RESULTS: AE-941 markedly inhibits the gelatinolytic activity of MMP-2 and to a lesser extent those of MMP-1, MMP-7, MMP-9 and MMP-13. AE-941 also inhibited the elastinolytic activities of MMP-2 and MMP-9 as well as MMP-12 (metalloelastase), porcine pancreatic elastase (PPE), and human leukocyte elastase (HLE). Western blot analysis revealed the presence within AE-941 of immunoreactive TIMP-like proteins, suggesting that these proteins may be at least partly responsible for the observed MMP inhibition.
CONCLUSIONS: Taken together, these results demonstrate that AE-941 contains TIMP-like proteins that could be responsible for the specific inhibition of MMPs. Given the recent studies suggesting the presence within this compound of specific inhibitor(s) of endothelial cell proliferation, AE-941 appears as a pleotropic agent able to interfere with several biochemical steps leading to angiogenesis and to other physiopathological conditions. Since AE-941 is currently under Phase III clinical investigations, these findings are also of considerable importance for our understanding of its anticancer properties.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11299728

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Matrix metalloproteinase inhibitors.

Authors:  Nithya Ramnath; Patrick J Creaven
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity.

Authors:  Denis Gingras; Dominique Labelle; Carine Nyalendo; Dominique Boivin; Michel Demeule; Chantal Barthomeuf; Richard Béliveau
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

3.  Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.

Authors:  Charles Lu; J Jack Lee; Ritsuko Komaki; Roy S Herbst; Lei Feng; William K Evans; Hak Choy; Pierre Desjardins; Benjamin T Esparaz; Mylene T Truong; Scott Saxman; Joseph Kelaghan; Archie Bleyer; Michael J Fisch
Journal:  J Natl Cancer Inst       Date:  2010-05-26       Impact factor: 13.506

Review 4.  The essential anti-angiogenic strategies in cartilage engineering and osteoarthritic cartilage repair.

Authors:  Song Chen; Yixuan Amy Pei; Ming Pei
Journal:  Cell Mol Life Sci       Date:  2022-01-14       Impact factor: 9.261

5.  Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats.

Authors:  Jing-Wei Mao; Xiao-Mei He; Hai-Ying Tang; Ying-De Wang
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 6.  Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.

Authors:  Chen Zhang; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2009-03-31       Impact factor: 5.118

7.  Matrilin-1 is an inhibitor of neovascularization.

Authors:  Matthew J Foradori; Qian Chen; Cecilia A Fernandez; Jay Harper; Xin Li; Paul C W Tsang; Robert Langer; Marsha A Moses
Journal:  J Biol Chem       Date:  2014-04-01       Impact factor: 5.157

Review 8.  Marine-derived angiogenesis inhibitors for cancer therapy.

Authors:  Ying-Qing Wang; Ze-Hong Miao
Journal:  Mar Drugs       Date:  2013-03-15       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.